NANOVIBRONIX TO SHOWCASE PAINSHIELD PRODUCTS AT 75TH ANNUAL WORKERS’ COMPENSATION EDUCATIONAL CONFERENCE DECEMBER 12-15
December 08 2021 - 8:30AM
NanoVibronix, Inc., (NASDAQ: NAOV), a healthcare device company
that produces the UroShield® and PainShield® Surface Acoustic
Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced
it will showcase its PainShield products at the Workers’
Compensation Institute’s (WCI) 75th Annual Workers’ Compensation
Educational Conference on December 12-15, 2021 at the Orlando World
Center Marriott in Orlando, Florida.
Brian Murphy, CEO of Nanovibronix, stated, “The workers’
compensation market represents an enormous opportunity for our pain
management devices. We are a new entrant to this market with the
recent signing of an agreement with a national provider of
solutions to facilitate reimbursement of our products. We look
forward to engaging in discussions with other workers’ comp payers
at the conference to educate on the benefits and superiority of our
PainShield products. Our goal within the Workers’
Compensation channel is to increase brand recognition and
accelerate availability.”
PainShield is an ultrasound device that delivers a localized
ultrasound effect to treat pain and induce soft tissue healing in a
targeted area, while keeping the level of ultrasound energy at a
safe and consistent level. Its range of applications includes acute
and chronic pain resolution through its many mechanisms of action.
The product has broad applications for sports injuries. PainShield
can be used by patients at home or work or in a clinical setting
and can be used even while the patient is sleeping. Patient
benefits include ease of application and use, faster recovery time,
high compliance, and increased safety and efficacy over existing
devices that rely on higher-frequency ultrasound.
About Workers’ Compensation Institute
The Workers’ Compensation Institute (WCI) is a nonprofit
educational organization that serves as a comprehensive resource to
all workers’ compensation stakeholders. WCI sponsors the annual
Workers’ Compensation Educational Conference and brings together
workers’ compensation professionals from across the country. It is
the nation’s largest work comp conference and the programming,
networking, exhibit hall, and entertainment cannot be matched.
For additional information about the conference, please visit:
https://www.wci360.com/conference/
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®
and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
Brett Maas, Managing Principal
Hayden IR, LLC
646-536-7331
brett@haydenir.com
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024